Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node

Journal of the National Cancer Institute

Volumn 100, Issue 22, 2008, Pages 1574-1580

  Van Deurzen, Carolien H M ^a   De Boer, Maaike ^b,c   Monninkhof, Evelyn M ^a   Bult, Peter ^d   Van Der Wall, Elsken ^a   Tjan Heijnen, Vivianne C G ^b   Van Diest, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CELL; CANCER STAGING; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW;

AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY;

EID: 56749171096     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn343     Document Type: Review

References (57)

1. Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06: 10-year pathologic and clinical prognostic discriminants. Cancer. 1993;71(8):2507-2514.
2. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-553.
3. van der Heiden van der Loo, Bezemer PD, Hennipman A, et al. Introduction of sentinel node biopsy and stage migration of breast cancer. Eur J Surg Oncol. 2006;32(7):710-714.
4. Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003;39(12):1654-1667.
5. Singletary SE, Greene FL. Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol. 2003;21(1):53-59.
6. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 2003;98(12):2740-2741.
7. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628-3636.
8. van-Iterson V, Leidenius M, Krogerus L, von-Smitten K. Predictive factors for the status of non-sentinel nodes in breast cancer patients with tumor positive sentinel nodes. Breast Cancer Res Treat. 2003;82(1):39-45.
9. Nos C, Harding-MacKean C, Freneaux P, et al. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg. 2003;90(11):1354-1360.
10. Yu JC, Hsu GC, Hsieh CB, Sheu LF, Chao TY. Prediction of metastasis to non-sentinel nodes by sentinel node status and primary tumor characteristics in primary breast cancer in Taiwan. World J Surg. 2005;29(7):813-818.
11. Cserni G, Gregori D, Merletti F, et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004;91(10):1245-1252.
12. Houvenaeghel G, Nos C, Mignotte H, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement - Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol. 2006;24(12):1814-1822.
13. Menes TS, Tartter PI, Mizrachi H, Constantino J, Estabrook A, Smith SR. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg. 2005;200(3):323-327.
14. Viale G, Maiorano E, Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319-325.
15. Rothman KJ. Epidemiology. An Introduction. New York: Oxford University Press; 2002.
16. Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol. 2008;61(1):41-51.
17. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9(1):1-30.
18. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care. Meta-analysis in Context. London: BMJ Publishing Group; 2001:189-208.
19. Delaloye JF, Monod JF, Friedli A, et al. Un reseau pour la recherche du ganglion sentinelle du cancer du sein. [Network for sentinel lymph node research in breast cancer]. Rev Med Suisse Romande. 2003;123(5):299-302.
20. Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol. 2003;10(6):622-627.
21. McCready DR, Yong WS, Ng AK, Miller N, Done S, Youngson B. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst. 2004;96(11):873-875.
22. Dabbs DJ, Fung M, Landsittel D, McManus K, Johnson R. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J. 2004;10(2):101-105.
23. Zgajnar J, Besic N, Podkrajsek M, Hertl K, Frkovic-Grazio S, Hocevar M. Minimal risk of macrometastases in the non-sentinel axillary lymph nodes in breast cancer patients with micrometastatic sentinel lymph nodes and preoperatively ultrasonically uninvolved axillary lymph nodes. Eur J Cancer. 2005;41(2):244-248.
24. Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J. 2004;10(5):392-397.
25. Leidenius MH, Vironen JH, Riihela MS, et al. The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Eur J Surg Oncol. 2005;31(1):13-18.
26. Viale G, Maiorano E, Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241(2):319-325.
27. Schrenk P, Konstantiniuk P, Wolfl S, et al. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg. 2005;92(6):707-713.
28. de Widt-Levert L, Tjan-Heijnen V, Bult P, Ruers T, Wobbes T. Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro-metastases in the sentinel lymph node. Eur J Surg Oncol. 2003;29(3):216-220.
29. Klevesath MB, Bobrow LG, Pinder SE, Purushotham AD. The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer. Br J Cancer. 2005;92(12):2201-2205.
30. Calhoun KE, Hansen NM, Turner RR, Giuliano AE. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection. Am J Surg. 2005;190(4):588-591.
31. Krauth JS, Charitansky H, Isaac S, Bobin JY. Clinical implications of axillary sentinel lymph node 'micrometastases ' in breast cancer. Eur J Surg Oncol. 2006;32(4):400-404.
32. Choi YJ, Yun HR, Yoo KE, et al. Intraoperative examination of sentinel lymph nodes by ultrarapid immunohistochemistry in breast cancer. Jpn J Clin Oncol. 2006;36(8):489-493.
33. van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HS, Rutgers EJ, Kroon BB. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer. 2006;107(3):467-471.
34. Amin BD, Hoda SA. Minimal metastatic disease in sentinel lymph nodes in breast carcinoma: some modest proposals to refine criteria for "isolated tumor cells. Adv Anat Pathol. 2006;13(4):185-189.
35. Falconieri G, Pizzolitto S, Gentile G. Comprehensive examination of sentinel lymph node in breast cancer: a solution without a problem? Int J Surg Pathol. 2006;14(1):1-8.
36. Ryden L, Chebil G, Sjostrom L, Pawlowski R, Jonsson PE. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol. 2007;33(1):33-38.
37. Bolster MJ, Peer PG, Bult P, et al. Risk factors for non-sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study. Ann Surg Oncol. 2007;14(1):181-189.
38. Groen RS, Oosterhuis AW, Boers JE. Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications. Breast Cancer Res Treat. 2007;105(1):1-5.
39. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245(3):452-461.
40. Fait V, Chrenko V. Sentinel node biopsy in breast cancer: short time results show appropriate regional control. Neoplasma. 2007;54(3):256-261.
41. Herbert GS, Sohn VY, Brown TA. The impact of nodal isolated tumor cells on survival of breast cancer patients. Am J Surg. 2007;193(5):571-573.
42. Cserni G, Burzykowski T, Vinh-Hung V, et al. Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol. 2004;34(9):519-524.
43. Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol. 2006;59(5):518-522.
44. Cserni G, Bianchi S, Vezzosi V, et al. Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study. Pathol Oncol Res. 2007;13(1):5-14.
45. van Deurzen CH, van Hillegersberg R, Hobbelink MG, Seldenrijk CA, Koelemij R, van Diest PJ. Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Cell Oncol. 2007;29(6):497-505.
46. Chu KU, Turner RR, Hansen NM, Brennan MB, Giuliano AE. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 1999;6(8):756-761.
47. Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer. 2005;103(2):358-367.
48. Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. (2):63.
49. Cserni G, Amendoeira I, Apostolikas N, et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol. 2004;57(7):695-701.
50. Degnim AC, Griffith KA, Sabel MS, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer. 2003;98(11):2307-2315.
51. Wada N, Imoto S. Clinical evidence of breast cancer micrometastasis in the era of sentinel node biopsy. Int J Clin Oncol. 2008;13(1):24-32.
52. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-7720.
53. Goyal A, Newcombe RG, Chhabra A, Mansel RE; on behalf of the ALMANAC-Trialists-Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203-208.
54. Guenther JM, Hansen NM, Difronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138(1):52-56.
55. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micro-metastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005;241(1):152-158.
56. Hwang RF, Gonzalez-Angulo AM, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110(4):723-730.
57. Vecchi M, Confalonieri S, Nuciforo P, et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene. 2007.